Related Experiment Video
Updated: Oct 13, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
Published on: April 4, 2022
Low-dose acebutolol given once daily in the treatment of chronic angina pectoris
I L Piña1, E V Smith, D J Weidler
1Division of Cardiology, University of Miami School of Medicine, Florida.
Insights
Once-daily acebutolol effectively manages chronic stable angina pectoris. This beta blocker significantly improved exercise hemodynamics and reduced ST depression without adverse effects.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acebutolol is a beta-1 selective beta blocker with intrinsic sympathomimetic activity.
- It is effective for chronic angina pectoris with multiple daily doses.
Purpose of the Study:
- To evaluate the long-term effects of once-daily acebutolol (400 mg) versus placebo.
- Assess impact on exercise hemodynamics, ST segment depression, and rate pressure product.
Main Methods:
- Eleven patients with hypertension and chronic angina pectoris were enrolled.
- A randomized, placebo-controlled study was conducted.
- Exercise treadmill tests were used for objective measurements.
Main Results:
- Once-daily acebutolol significantly reduced peak heart rate, systolic blood pressure, and rate pressure product during exercise.
- Significant reduction in ST segment depression was observed with acebutolol.
- No significant adverse effects were reported during the study.
Conclusions:
- Once-daily acebutolol (400 mg) is efficacious for chronic stable angina pectoris.
- This dosing regimen improves exercise hemodynamics and reduces ischemic indicators.
- Acebutolol offers a convenient once-daily treatment option for angina.
Abstract:
Acebutolol, a beta-1 selective beta blocker with intrinsic sympathomimetic activity has been shown to be an effective agent in chronic angina pectoris therapy, with twice or three times daily dosing. The long-term effects of 400 mg of acebutolol given only once a day versus placebo on exercise hemodynamics, ST segment depression, and rate pressure product were studied. Eleven patients (mean age, 60 +/- 12 years) with hypertension and chronic angina pectoris were enrolled. Resting heart rate was not significantly altered after therapy, (80 vs 72 bpm). Objective measurements from exercise treadmill tests showed significant reduction in peak heart rate from 130 to 103 bpm, systolic blood pressure from 197 to 167 mm Hg, rate pressure product (from 25 to 18 bpm-mm Hg X 1000), and ST depression in patients receiving acebutolol compared with those receiving placebo. No significant adverse effects were reported. These data indicate that acebutolol may be efficacious as once daily therapy for chronic stable angina pectoris.
More Related Videos
02:34Auricular Acupressure as an Adjuvant Treatment for Wheezing in Stable Chronic Obstructive Pulmonary Disease
Published on: May 10, 2024
04:24Acupoint Application as a Traditional Chinese Medicine Treatment for Fatigue Associated with Chronic Obstructive Pulmonary Disease
Published on: September 5, 2025
Related Concept Videos
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
COPD: Management Using Bronchodilators and Corticosteroids
Angina IV: Management